Published in Mol Immunol on February 19, 2008
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther (2009) 1.32
A transcription factor map as revealed by a genome-wide gene expression analysis of whole-blood mRNA transcriptome in multiple sclerosis. PLoS One (2010) 1.00
Effects of activating NK cell receptor expression and NK cell reconstitution on the outcomes of unrelated donor hematopoietic cell transplantation for hematologic malignancies. Leukemia (2009) 0.97
Cord Blood as a Source of Natural Killer Cells. Front Med (Lausanne) (2016) 0.84
Viral infection transiently reverses activation receptor-mediated NK cell hyporesponsiveness in an MHC class I-independent mechanism. Eur J Immunol (2013) 0.80
Importance of killer immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Hemoter (2011) 0.77
KIR repertory in patients with hematopoietic diseases and healthy family members. BMC Hematol (2016) 0.75
High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med (2009) 4.90
Cytarabine dose for acute myeloid leukemia. N Engl J Med (2011) 4.15
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood (2002) 3.56
Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol (2005) 3.15
An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet (2005) 3.04
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood (2008) 2.35
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. J Clin Oncol (2013) 2.22
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood (2002) 2.01
Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res (2006) 1.84
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica (2005) 1.75
HER-2/neu amplification testing in breast cancer by multiplex ligation-dependent probe amplification in comparison with immunohistochemistry and in situ hybridization. Cell Oncol (2009) 1.70
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma. N Engl J Med (2015) 1.70
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol (2010) 1.64
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood (2007) 1.60
Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol (2012) 1.60
Criteria for defining a complete remission in acute myeloid leukaemia revisited. An analysis of patients treated in HOVON-SAKK co-operative group studies. Br J Haematol (2005) 1.54
Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2007) 1.50
The association of CD25 expression on donor CD8+ and CD4+ T cells with graft-versus-host disease after donor lymphocyte infusions. Haematologica (2005) 1.49
Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. J Clin Oncol (2006) 1.42
NOD2/CARD15 variants are not a risk factor for clinical outcome after nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant (2011) 1.41
A brief history of pathology: Preface to a forthcoming series that highlights milestones in the evolution of pathology as a discipline. Virchows Arch (2010) 1.32
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. J Clin Oncol (2012) 1.30
Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood (2004) 1.30
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. Blood (2003) 1.26
Unison or cacophony: postgraduate training in pathology in Europe. Virchows Arch (2009) 1.21
The pathology of bone marrow failure. Histopathology (2010) 1.16
Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood (2005) 1.14
The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood (2004) 1.11
Rituximab treatment before reduced-intensity conditioning transplantation associates with a decreased incidence of extensive chronic GVHD. Biol Blood Marrow Transplant (2009) 1.08
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev (2007) 1.07
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood (2010) 1.07
Allogeneic stem-cell transplantation for blastic plasmacytoid dendritic cell neoplasm. J Clin Oncol (2012) 1.06
Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev (2003) 1.06
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. Blood (2011) 1.01
A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies. Exp Hematol (2003) 1.01
Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood (2002) 0.99
Forced overexpression of either of the two common human Foxp3 isoforms can induce regulatory T cells from CD4(+)CD25(-) cells. Eur J Immunol (2008) 0.97
p53 mutation analysis for definite diagnosis of multiple primary lung carcinoma. Cancer (2002) 0.94
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood (2008) 0.92
Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica (2007) 0.92
Antithymocyteglobulin as prophylaxis of graft failure and graft-versus-host disease in recipients of partially T-cell-depleted grafts from matched unrelated donors: a dose-finding study. Exp Hematol (2003) 0.91
Influence of cytomegalovirus seropositivity on outcome after T cell-depleted bone marrow transplantation: contrasting results between recipients of grafts from related and unrelated donors. Clin Infect Dis (2002) 0.90
Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant (2007) 0.90
Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol (2009) 0.89
Acute renal failure after nonmyeloablative stem cell transplantation in adults. Biol Blood Marrow Transplant (2008) 0.88
Extra-domain-A fibronectin: a new marker of fibrosis in cutaneous graft-versus-host disease. J Invest Dermatol (2004) 0.88
A compulsory examination in pathology: redundant or necessary? Virchows Arch (2012) 0.86
Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol (2002) 0.86
HLA and MICA associations with head and neck squamous cell carcinoma. Oral Oncol (2006) 0.84
Prognostic relevance of immunohistochemical subclassification of diffuse large B-cell lymphoma in two prospective phase III clinical trials. Clin Lymphoma Myeloma Leuk (2011) 0.84
Results of hematopoietic stem cell transplantation after treatment with different high-dose total-body irradiation regimens in five Dutch centers. Int J Radiat Oncol Biol Phys (2008) 0.84
Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol (2003) 0.84
Cataract after total body irradiation and bone marrow transplantation: degree of visual impairment. Int J Radiat Oncol Biol Phys (2002) 0.83
Cardiomyocyte death in patients with end-stage heart failure before and after support with a left ventricular assist device: low incidence of apoptosis despite ubiquitous mediators. J Heart Lung Transplant (2003) 0.82
Effect of antithymocyte globulin on quantitative immune recovery and graft-versus-host disease after partially T-cell-depleted bone marrow transplantation: a comparison between recipients of matched related and matched unrelated donor grafts. Transplantation (2003) 0.82
Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol (2008) 0.81
Downregulation of SERPINB13 expression in head and neck squamous cell carcinomas associates with poor clinical outcome. Int J Cancer (2009) 0.81
Acute cardiac transplant rejection is associated with low frequencies of interleukin-4 producing helper T-lymphocytes rather than with interleukin-4 promoter or splice variants. Hum Immunol (2002) 0.81
Deletion of chromosomal region 6q14-16 in prostate cancer. Int J Cancer (2002) 0.81
Patients benefit from the addition of KIR repertoire data to the donor selection procedure for unrelated haematopoietic stem cell transplantation. Mol Immunol (2007) 0.81
The elucidation of KIR2DL4 gene polymorphism. Mol Immunol (2007) 0.79
No association between transforming growth factor beta gene polymorphism and acute allograft rejection after cardiac transplantation. Transpl Immunol (2002) 0.79
Donor interleukin-4 promoter gene polymorphism influences allograft rejection after heart transplantation. J Heart Lung Transplant (2002) 0.79
Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A. Cancer Immunol Immunother (2015) 0.79
Stem cell transplantation nephropathy: a report of six cases. Biol Blood Marrow Transplant (2007) 0.79
Identification of HLA-A*0111N: a synonymous substitution, introducing an alternative splice site in exon 3, silenced the expression of an HLA-A allele. Hum Immunol (2005) 0.78
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica (2009) 0.78
Similar left and right ventricular sarcomere structure after support with a left ventricular assist device suggests the utility of right ventricular biopsies to monitor left ventricular reverse remodeling. Int J Cardiol (2005) 0.78
Extended HLA-DPB1 polymorphism: an RNA approach for HLA-DPB1 typing. Immunogenetics (2005) 0.78
Molecular typing of HLA-E. Methods Mol Biol (2012) 0.77
Genes in the HLA region indicative for head and neck squamous cell carcinoma. Mol Immunol (2006) 0.77
Autopsy pathology should become a recognised subspecialty. Virchows Arch (2008) 0.77
Cost determinants in aggressive non-Hodgkin's lymphoma. Haematologica (2005) 0.77